期刊的影响因子--文章列表

期刊文章列表
Yang He^1,2,3,4，Yuefei Fang^1,5，Meng Zhang^1,6，Yuge Zhao¹，Bin Tu^1,2，Mingjie Shi¹，Bahtiyor Muhitdinov^1,7，Akmal Asrorov^1,7，Qin Xu⁵，Yongzhuo Huang^1,2,3,8（State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；Zhongshan Institute for Drug Discovery，Chinese Academy of Sciences；Department of Pharmacy，the First Affiliated Hospital of Zhengzhou University；Artemisinin Research Center，Guangzhou University of Chinese Medicine；Women's Hospital，School of Medicine，Zhejiang University；Institute of Bioorganic Chemistry，Uzbekistan Academy of Sciences；National Medical Products Administration，Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients）.Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona[J].Acta Pharmaceutica Sinica B,2022,第4期 Shuai Guo，Kening Li，Yanwen Chen，Bin Li（State Key Laboratory of Natural Medicines and School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Unraveling the drug distribution in brain enabled by MALDI MS imaging with laser-assisted chemical transfer[J].Acta Pharmaceutica Sinica B,2022,第4期 Yongrong Yao，Huachao Chen，Ninghua Tan（State Key Laboratory of Natural Medicines，School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiqiang Deng¹，Yu Dong¹，Xiaoting Zhou^2,3，Jia-Hong Lu¹，Zhenyu Yue²（State Key Laboratory of Quality Research in Chinese Medicine，Institute of Chinese Medical Sciences，University of Macau；Department of Neurology，the Friedman Brain Institute，Icahn School of Medicine at Mount Sinai；Department of Geriatrics，Xiangya Hospital，Central South University）.Pharmacological modulation of autophagy for Alzheimer’s disease therapy：Opportunities and obstacles[J].Acta Pharmaceutica Sinica B,2022,第4期 Jie Zhou¹，Wei Xu¹，Zezhong Liu¹，Chao Wang²，Shuai Xia¹，Qiaoshuai Lan¹，Yanxing Cai¹，Shan Su¹，Jing Pu¹，Lixiao Xing¹，Youhua Xie¹，Lu Lu¹，Shibo Jiang¹，Qian Wang¹（Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)，School of Basic Medical Sciences and BSL-3 Facility，Shanghai Institute of Infectious Diseases and Biosecurity，Fudan University；State Key Laboratory of Toxicology and Medical Countermeasures，Beijing Institute of Pharmacology and Toxicology）.A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases[J].Acta Pharmaceutica Sinica B,2022,第4期 Sameera Senaweera¹，Tiffany C.Edwards¹，Jayakanth Kankanala¹，Yan Wang^1,2，Rajkumar Lalji Sahani¹，Jiashu Xie¹，Robert J.Geraghty¹，Zhengqiang Wang¹（Center for Drug Design，College of Pharmacy，University of Minnesota；Translational Medicine R&D Center，Shenzhen Institutes of Advanced Technology，Chinese Academy of Sciences）.Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus（HCMV）[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhidi Pan¹，Jie Chen¹，Xiaodong Xiao^2,3，Yueqing Xie²，Hua Jiang^2,3，Baohong Zhang¹，Huili Lu¹，Yunsheng Yuan¹，Lei Han³，Yuexian Zhou¹，Huifang Zong¹，Lei Wang¹，Rui Sun¹，Jianwei Zhu^1,2,3（Engineering Research Center of Cell&Therapeutic Antibody，MOE，School of Pharmacy，Shanghai Jiao Tong University；Jecho Laboratories，Inc.；Jecho Biopharmaceuticals Co.，Ltd.）.Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement[J].Acta Pharmaceutica Sinica B,2022,第4期 Xuejing Shao¹，Yingqian Chen¹，Wei Wang¹，Wenxin Du¹，Xingya Zhang¹，Minyi Cai¹，Shaowei Bing¹，Ji Cao^1,2,3，Xiaojun Xu⁴，Bo Yang^1,3，Qiaojun He^1,2,3，Meidan Ying^1,4,2（Institute of Pharmacology and Toxicology，Zhejiang Province Key Laboratory of Anti-Cancer Drug Research，College of Pharmaceutical Sciences，Zhejiang University；Cancer Center，Zhejiang University；Innovation Institute for Artificial Intelligence in Medicine，Zhejiang University；Children's Hospital，Zhejiang University School of Medicine，National Clinical Research Center for Child Health）.Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells[J].Acta Pharmaceutica Sinica B,2022,第4期 Jun Wang，Yanmei Hu，Madeleine Zheng（Department of Pharmacology and Toxicology，College of Pharmacy，the University of Arizona）.Enterovirus A71 antivirals：Past, present, and future[J].Acta Pharmaceutica Sinica B,2022,第4期 Yunlong Shan¹，Qi Ni¹，Qixiang Zhang¹，Mengying Zhang¹，Bin Wei²，Lingge Cheng¹，Chongjin Zhong¹，Xinyu Wang¹，Qingqing Wang¹，Jiali Liu¹，Jingwei Zhang¹，Jingjing Wu²，Guangji Wang¹，Fang Zhou¹（Key Laboratory of Drug Metabolism and Pharmacokinetics，State Key Laboratory of Natural Medicines，China Pharmaceutical University；Department of Hematology and Oncology，the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University）.Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment[J].Acta Pharmaceutica Sinica B,2022,第4期 Xueqin He¹，Xiaorong Wang¹，Lianyi Yang¹，Zhihang Yang¹，Wenqi Yu¹，Yazhen Wang¹，Rui Liu¹，Meiwan Chen²，Huile Gao¹（Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province，Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology，West China School of Pharmacy，Sichuan University；State Key Laboratory of Quality Research in Chinese Medicine，Institute of Chinese Medical Sciences，University of Macau）.Intelligent lesion blood-brain barrier targeting nano-missiles for Alzheimer’s disease treatment by anti-neuroinfiammation and neuroprotection[J].Acta Pharmaceutica Sinica B,2022,第4期 Mélanie Robert^1,2,3，Bastien Laperrousaz¹，Diana Piedrahita¹，Emilie-Fleur Gautier^3,4，Travis Nemkov^5,6，Florian Dupuy^4,7，Elie Nader^2,3，Virginie Salnot⁴，Patrick Mayeux^3,4，Angelo D’Alessandro^5,6，Catherine Lavazec^4,7，Philippe Joly^2,3,8，Alexander Scheer¹，Philippe Connes^2,3，Agnès Cibiel¹（Erytech Pharma；Laboratoire interuniversitaire de Biologie de la Motricité(LIBM)EA7424，Team?Vascular Biology and Red Blood Cell?，Université Claude Bernard Lyon 1，Université de Lyon；Labex GR-Ex；3P5 proteom’IC facility，Université de Paris，Institut Cochin，INSERM，CNRS；University of Colorado，Anschutz Medical Campus；Omix Technologies，Inc.；Inserm U1016，CNRS 8104，Université de Paris，Institut Cochin；Laboratoire de Biochimie et de Biologie Moléculaire，UF de biochimie des pathologies érythrocytaires，Centre de Biologie et de Pathologie Est，Hospices Civils de Lyon）.Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process[J].Acta Pharmaceutica Sinica B,2022,第4期 Lei Feng^1,2，Xiangge Tian²，Dahong Yao³，Zhenlong Yu²，Xiaokui Huo^1,2，Zhenhao Tian⁴，Jing Ning²，Jingnan Cui⁴，Tony D.James^5,6，Xiaochi Ma^1,2（Second Affiliated Hospital，Dalian Medical University；College of Pharmacy，the National&Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease，Dalian Medical University；School of Pharmaceutical Sciences，Shenzhen Technology University；State Key Laboratory of Fine Chemicals，Dalian University of Technology；Department of Chemistry，University of Bath；School of Chemistry and Chemical Engineering，Henan Normal University）.A practical strategy to develop isoform-selective near-infrared fiuorescent probes for human cytochrome P450 enzymes[J].Acta Pharmaceutica Sinica B,2022,第4期 Chunlong Ma，Haozhou Tan，Juliana Choza，Yuyin Wang，Jun Wang（Department of Pharmacology and Toxicology，College of Pharmacy，the University of Arizona）.Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays[J].Acta Pharmaceutica Sinica B,2022,第4期 Rong Xiang¹，Zhengsen Yu¹，Yang Wang¹，Lili Wang²，Shanshan Huo¹，Yanbai Li¹，Ruiying Liang¹，Qinghong Hao¹，Tianlei Ying³，Yaning Gao⁴，Fei Yu¹，Shibo Jiang³（College of Life Sciences，Hebei Agricultural University；Research Center of Chinese Jujube，Hebei Agricultural University；Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)，School of Basic Medical Sciences，Shanghai Institute of Infectious Diseases and Biosecurity，Fudan University；Beijing Pharma and Biotech Center）.Recent advances in developing small-molecule inhibitors against SARS-CoV-2[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiwei Xiao^1,2，Huiyi Wei¹，Yi Xu³，Ahmed Haider²，Junjie Wei¹，Shiyu Yuan¹，Jian Rong²，Chunyu Zhao²，Guocong Li¹，Weibin Zhang⁴，Huangcan Chen⁴，Yuefeng Li⁵，Lingling Zhang¹，Jiyun Sun^1,2，Shaojuan Zhang¹，Hai-Bin Luo⁶，Sen Yan⁷，Qijun Cai¹，Lu Hou¹，Chao Che⁴，Steven H.Liang²，Lu Wang¹（Center of Cyclotron and PET Radiopharmaceuticals，Department of Nuclear Medicine and PET/CT-MRI Center，the First Affiliated Hospital of Jinan University；Division of Nuclear Medicine and Molecular Imaging，Massachusetts General Hospital&Department of Radiology，Harvard Medical School；Department of Cardiology，the First Affiliated Hospital of Jinan University；State Key Laboratory of Chemical Oncogenomics，Key Laboratory of Chemical Genomics，Peking University Shenzhen Graduate School；Guangdong Landau Biotechnology Co.Ltd.；Key Laboratory of Tropical Biological Resources of Ministry of Education，School of Pharmaceutical Sciences，Hainan University；Guangdong-Hongkong-Macau Institute of CNS Regeneration，Ministry of Education CNS Regeneration Collaborative Joint Laboratory，Jinan University）.Discovery of a highly specific ¹⁸F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofiuorination[J].Acta Pharmaceutica Sinica B,2022,第4期 Wen-Xing Ding¹，Russell H.Swerdlow²（Department of Pharmacology，Toxicology and Therapeutics，Department of Internal Medicine，the University of Kansas Medical Center；Department of Neurology，the University of Kansas Medical Center）.Editorial of special column on Drug targets and drug development for Alzheimer’s disease[J].Acta Pharmaceutica Sinica B,2022,第4期 Hongxi Hu，Xiaotong Lu，Huiyan Xu，Liyun Zhou（Pharmcube（Beijing）Co.，Ltd.）.Analysis of new drug registration and review in China in 2021[J].Acta Pharmaceutica Sinica B,2022,第4期 Jun Wang¹，Hongmin Li²（Department of Medicinal Chemistry，Ernest Mario School of Pharmacy，Rutgers，the State University of New Jersey；Department of Pharmacology and Toxicology，College of Pharmacy，University of Arizona）.Editorial of Special Column on Antiviral Drug Discovery and Pharmacology[J].Acta Pharmaceutica Sinica B,2022,第4期 Songtao Dong¹，Xiangnan Guo¹，Fei Han²，Zhonggui He¹，Yongjun Wang¹（Department of Pharmaceutics，Wuya College of Innovation，Shenyang Pharmaceutical University；School of Pharmacy，Shenyang Pharmaceutical University）.Emerging role of natural products in cancer immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第3期 Zhiwei Fan^1,2，Changyue Wu^2,3，Miaomiao Chen²，Yongying Jiang⁴，Yuanyuan Wu²，Renfang Mao⁴，Yihui Fan^1,2（Department of Pathogenic Biology，School of Medicine，Nantong University；Laboratory of Medical Science，School of Medicine，Nantong University；Department of Dermatology，Affiliated Hospital of Nantong University，Nantong University；Department of Pathophysiology，School of Medicine，Nantong University）.The generation of PD-L1 and PD-L2 in cancer cells：From nuclear chromatin reorganization to extracellular presentation[J].Acta Pharmaceutica Sinica B,2022,第3期 Sha-Sha Cheng¹，Yuan-Qing Qu²，Jia Wu¹，Guan-Jun Yang^1,3,4，Hao Liu⁵，Wanhe Wang^5,6，Qi Huang²，Feng Chen¹，Guodong Li¹，Chun-Yuen Wong⁷，Vincent Kam Wai Wong²，Dik-Lung Ma⁵，Chung-Hang Leung^1,8（Institute of Chinese Medical Sciences and State Key Laboratory of Quality Research in Chinese Medicine，University of Macau；Dr.Neher's Biophysics Laboratory for Innovative Drug Discovery，State Key Laboratory of Quality Research in Chinese Medicine，Macau University of Science and Technology；State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products，Ningbo University；Laboratory of Biochemistry and Molecular Biology，School of Marine Sciences，Ningbo University；Department of Chemistry，Hong Kong Baptist University；Institute of Medical Research，Northwestern Polytechnical University；Department of Chemistry，City University of Hong Kong；Department of Biomedical Sciences，Faculty of Health Sciences，University of Macau）.Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer[J].Acta Pharmaceutica Sinica B,2022,第3期 Pearl Moharil，Zhuoya Wan，Apurva Pardeshi，Jiang Li，Haozhe Huang，Zhangyi Luo，Sanjay Rathod，Ziqian Zhang，Yuang Chen，Bei Zhang，Christian A.Fernandez，Jingjing Sun，Song Li（Center for Pharmacogenetics，Department of Pharmaceutical Science，School of Pharmacy，University of Pittsburgh）.Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy：Dual targeting of tumor cells and tumor-associated macrophages[J].Acta Pharmaceutica Sinica B,2022,第3期 Yunhao Wu，Xiu Yu，Yuwei Wang，Yalin Huang，Jiahui Tang，Shuaishuai Gong，Siyu Jiang，Yuanli Xia，Fang Li，Boyang Yu，Yuanyuan Zhang，Junping Kou（State Key Laboratory of Natural Medicines，Jiangsu Key Laboratory of TCM Evaluation and Translational Research，Department of Pharmacology of Chinese Material Medica，School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4signaling[J].Acta Pharmaceutica Sinica B,2022,第3期 Yingzi He^1,2，Zhiwei Zheng^1,2，Chang Liu^1,2，Wen Li^1,2，Liping Zhao^1,2，Guohui Nie³，Huawei Li^1,2,4,5（ENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital，State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science，Fudan University；NHC Key Laboratory of Hearing Medicine (Fudan University)；Department of Otolaryngology and Institute of Translational Medicine，Shenzhen Second People's Hospital/the First Affiliated Hospital of Shenzhen University Health Science Center；Institutes of Biomedical Sciences，Fudan University；The Institutes of Brain Science and the Collaborative Innovation Center for Brain Science，Fudan University）.Inhibiting DNA methylation alleviates cisplatininduced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosis via the LRP1-PI3K/AKT pathway[J].Acta Pharmaceutica Sinica B,2022,第3期首页上一页 6 7 8 9 10 下一页尾页共有12页，转到页

期刊文章列表